Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension

Hypertension

Volumn 54, Issue 4, 2009, Pages 731-737

  Reichek, Nathaniel ^a,b   Devereux, Richard B ^c   Rocha, Ricardo A ^d   Hilkert, Robert ^d   Hall, Donna ^d   Purkayastha, Das ^d   Pitt, Bertram ^e  

^a ST FRANCIS HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amlodipine; Combination therapy; Hydrochlorothiazide; Hypertension; Left ventricular hypertrophy regression; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GENDER; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; UNSPECIFIED SIDE EFFECT;

AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEART VENTRICLES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RISK FACTORS; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 70349680428     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.130641     Document Type: Article

References (39)

1. Agabiti-Rosei E. Assessment of preclinical target organ damage in hypertension: Left ventricular hypertrophy. J Hypertens. 2002;20:156-158.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
3. Vakili BA, Okin PM, Devereux RB. Prognostic significance of left ventricular hypertrophy. Am Heart J. 2001;141:334-341.
4. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
5. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54. (Pubitemid 28036154)
6. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin- converting enzyme inhibitor ramipril. Circulation. 2001;104: 1615-1621.
7. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. Am J Hypertens. 2003;16:895-899. (Pubitemid 37315486)
8. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Snapinn SM, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension: The LIFE Study. JAMA. 2004;292:2350-2356.
9. Gardin JM, Lauer MS. Left ventricular hypertrophy: The next treatable, silent killer? JAMA. 2004;292:2396-2398.
10. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500-505.
11. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
12. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlof B. Effects of once-daily angiotensinconverting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) Trial. Circulation. 2001;104:1248-1254.
13. Zhang R, Crump J, Reisin E. Regression of left ventricular hypertrophy is a key goal of hypertension management. Curr Hypertens Reports. 2003;5:301-308.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187. (Pubitemid 46924065)
16. Krauser DG, Devereux RB. Ventricular hypertrophy and hypertension: Prognostic elements and implications for management. Herz. 2006;31: 305-316.
17. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens. 2004;17:37-42.
18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the American College of Cardiology Echocardiography Committee, the American Heart Association, and the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
20. Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlöf B, Aalto T, Roman MJ, Papademetriou V, Ibsen H, Rokkedal J, Devereux RB. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: The LIFE study. Hypertension. 2000;35:6-12.
21. Rathi VK, Doyle M, Yamrozik J, Williams RB, Caruppannan K, Truman C, Vido D, Biederman RW. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: A practical approach. J Cardiovasc Magn Reson. 2008;10:36.
22. Dahlöf B, Gosse P, Guéret P, Dubourg O, de Simone G, Schmieder R, Karpov Y, García-Puig J, Matos L, De Leeuw PW, Degaute JP, Magometschnigg D; The PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: The PICXEL Study. J Hypertens. 2005;23:2063-2070.
23. Rajappan K, Bellenger NG, Anderson L, Pennell DJ. The role of cardiovascular magnetic resonance in heart failure. Eur J Heart Fail. 2000;2: 241-252.
24. de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, Romero R, De Leeuw PW, Hitzenberger G, Battegay E, Duprez D, Sever P, Safar ME. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: The REASON echocardiography study. Am J Hypertens. 2004;17: 660-667. (Pubitemid 39091546)
25. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B. Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention for Endpoint Reduction Study. J Hypertens. 2002;20:1445-1450. (Pubitemid 34925691)
26. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13:564-569.
27. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
28. Boydak B, Nalbantgil S, Yilmaz H, Zoghi M, Ozerkan F, Nalbantgil I, Onder R. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension. Saudi Med J. 2004;25: 1975-1978.
29. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-2349. (Pubitemid 39491918)
30. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, Hille DA, Lyle PA, Okin PM, Dahlöf B, Oparil S. Effects of losartan in women with hypertension and left ventricular hypertrophy: Results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51:1103-1108.
31. Llamas B, Jiang Z, Rainville ML, Picard S, Deschepper CF. Distinct QTLs are linked to cardiac left ventricular mass in a sex-specific manner in a normotensive inbred rat inter-cross. Mamm Genomics. 2005;16: 700-711.
32. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993;72:310-313.
33. Devereux RB, Bella JN, Boman K, Gerdts E, Nieminen MS, Rokkedal J, Papademetriou V, Wachtell K, Wright J, Paranicas M, Okin PM, Roman MJ, Dahlöf B. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press. 2001;10:74-82. (Pubitemid 32640567)
34. Aurigemma GP, Gaasch WH. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology. 1995;86: 310-317.
35. Villari B, Campbell SE, Schneider J, Vassalli G, Chiariello M, Hess OM. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J. 1995;16:1410-1419.
36. Deschepper CF, Llamas B. Hypertensive cardiac remodeling in males and females: from the bench to the bedside. Hypertension. 2007;49:401-407.
37. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
38. Janik M, Cham MD, Ross MI, Wang Y, Codella N, Min JK, Prince MR, Manoushagian S, Okin PM, Devereux RB, Weinsaft JW. Effects of papillary muscles and trabeculae on left ventricular quantification: increased impact of methodological variability in patients with left ventricular hypertrophy. J Hypertens. 2008;26:1677-1685.
39. Weinsaft JW, Cham MD, Janik M, Min JK, Henschke CI, Yankelevitz DF, Devereux RB. Left ventricular papillary muscles and trabeculae are significant determinants of cardiac MRI volumetric measurements: Effects on clinical standards in patients with advanced systolic dysfunction. Int J Cardiol. 2008;126:359-365.